Vorinostat Completed Phase 2 Trials for Primary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00132067Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer